Non-Oral Drug Delivery Strategies: From Early Diagnosis to Advanced Treatments - European Medical Journal

Continue

Non-Oral Drug Delivery Strategies: From Early Diagnosis to Advanced Treatments

Neurology
Download PDF

Summary of presentations from the Britannia-sponsored symposium held at the 1st Congress of the European Academy of Neurology (EAN), Berlin, Germany, on 21st June

Chairpeople:
Claudia Trenkwalder,1 Werner Poewe2
Speakers:
Werner Poewe,2 Fabrizio Stocchi,3 Stuart H. Isaacson4

1. University Medical Centre of Göttingen, Göttingen; and Paracelsus Elena Klinik, Center of Parkinsonism and Movement Disorders, Kassel, Germany
2. Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
3. Institute of Research and Medical Care, IRCCS San Raffaele, Rome, Italy
4. Florida International University, Herbert Wertheim College School of Medicine, Miami; Parkinson’s Disease and Movement Disorders Center of Boca Raton, Boca Raton; and Marcus Neuroscience Institute, Boca Raton Regional Hospital, Boca Raton, Florida, USA

Disclosure:

C. Trenkwalder has received personal fees for advisory boards from Mundipharma, UCB, Vifor Pharma, Britannia Pharmaceuticals, and Novartis; she has also received payments for lectures from UCB, AstraZeneca, and Desitin; and has received royalties from Schattauer Verlag. W. Poewe has received personal fees from Britannia for consultancy and lecture fees in relation to clinical drug development programmes for Parkinson’s disease (PD); he has also received personal fees from AbbVie, AstraZeneca, Britannia, Lundbeck, Teva, Novartis, GSK, Boehringer-Ingelheim, UCB, Orion Pharma, Zambon, and Merz Pharmaceuticals for consultancy and lecture fees in relation to clinical drug development programmes for PD, outside of the submitted work; and has received royalties from Thieme, Wiley Blackwell, and Oxford University Press. F. Stocchi has received honoraria for participation in scientific advisory boards for GSK, Teva, Boehringer Ingelheim, Newron, Merck Serono, Novartis, Lundbeck, Impax, Schering-Plough, MSD, and UCB; and has received speaker fees for educational lectures for GSK, Teva, Boehringer Ingelheim, Merck Serono, Novartis, Lundbeck, UCB, and Britannia. S. H. Isaacson has received honoraria for CME activities, research grants and/or consultant and promotional speaker fees from AbbVie, Acadia, Adamas, Addex, Allergan, Allon, AstraZeneca, Biotie, Britannia, Chelsea, Civitas, Eisai, GE, GSK, Impax, Ipsen, Kyowa, Lilly, Merck Schering-Plough, Medtronics, Merz, Michael J. Fox Foundation, Novartis, Neurocrine, National Institutes of Health (NIH), Novartis, Orion, Parkinson Study Group, Phytopharm, Purdue, Roche, Santhera, Serono, Shire, Teva, UCB, and US World Meds.

Acknowledgements:

Writing assistance was provided by Dr Karen Wolstencroft, Helen Lawn Associates PR Limited.

Support:

This symposium and the publication of this article was funded by Britannia Pharmaceuticals Limited. The views and opinions expressed are those of the authors and not necessarily of Britannia Pharmaceuticals Limited.

Citation:
EMJ Neurol. ;3[1]:40-49. DOI/10.33590/emjneurol/10314470. https://doi.org/10.33590/emjneurol/10314470.
Keywords:
EAN 2015, European Academy of Neurology

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

This educational symposium, sponsored by Britannia Pharmaceuticals Limited, was held during the 1st Congress of the European Academy of Neurology (EAN), which took place from 20th-23rd June 2015 in Berlin, Germany. The symposium reviewed the role of non-oral drug delivery strategies in patients with Parkinson’s disease (PD) and how they can overcome problems that occur with the gastrointestinal (GI) route of administration in many patients. GI dysfunction is recognised as a common problem in PD and may in fact be a preclinical marker of the disease. It can affect the absorption of oral medication resulting in OFF periods and unreliable control of motor symptoms, which in turn can have a negative impact on quality of life (QoL). Delayed time-to-ON (TTO) after an oral levodopa dose and dose failures are known to be significant contributors to total OFF time. Results of the recently completed AM-IMPAKT trial in patients with morning akinesia due to a delay in the onset of oral levodopa effect demonstrate that apomorphine intermittent injection (penject) is able to provide rapid and effective resolution of such complications, restoring patients to the ON state quickly and allowing them to get on with their daily activities.

Please view the full content in the PDF above. 

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given